Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Catherine Ju-Ying Wu, M.D.

Co-Author

This page shows the publications co-authored by Catherine Wu and Donna Neuberg.
Connection Strength

7.287
  1. Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood. 2022 Apr 07; 139(14):2252-2256.
    View in: PubMed
    Score: 0.249
  2. Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. Cancer Discov. 2021 Dec 01; 11(12):3048-3063.
    View in: PubMed
    Score: 0.243
  3. Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case. Blood Adv. 2021 11 23; 5(22):4701-4709.
    View in: PubMed
    Score: 0.243
  4. Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Cell Rep. 2021 11 09; 37(6):109992.
    View in: PubMed
    Score: 0.242
  5. Activation of Notch and Myc Signaling via B-cell-Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. Cancer Res. 2021 12 15; 81(24):6117-6130.
    View in: PubMed
    Score: 0.241
  6. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature. 2021 08; 596(7870):119-125.
    View in: PubMed
    Score: 0.237
  7. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 06 10; 137(23):3212-3217.
    View in: PubMed
    Score: 0.235
  8. A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell. 2021 03 08; 39(3):380-393.e8.
    View in: PubMed
    Score: 0.231
  9. Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clin Cancer Res. 2021 09 15; 27(18):5049-5061.
    View in: PubMed
    Score: 0.228
  10. High throughput single-cell detection of multiplex CRISPR-edited gene modifications. Genome Biol. 2020 10 20; 21(1):266.
    View in: PubMed
    Score: 0.225
  11. Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 09 16; 12(561).
    View in: PubMed
    Score: 0.224
  12. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019 10 14; 36(4):369-384.e13.
    View in: PubMed
    Score: 0.209
  13. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019 06; 570(7762):474-479.
    View in: PubMed
    Score: 0.204
  14. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19).
    View in: PubMed
    Score: 0.195
  15. A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood. 2018 11 01; 132(18):1911-1921.
    View in: PubMed
    Score: 0.194
  16. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. 2018 04 19; 173(3):624-633.e8.
    View in: PubMed
    Score: 0.189
  17. Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2018 03 14; 555(7696):402.
    View in: PubMed
    Score: 0.188
  18. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017 12 19; 8(1):2185.
    View in: PubMed
    Score: 0.185
  19. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 07 13; 547(7662):217-221.
    View in: PubMed
    Score: 0.179
  20. Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. Genome Res. 2017 08; 27(8):1300-1311.
    View in: PubMed
    Score: 0.179
  21. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. 2016 Nov 14; 30(5):750-763.
    View in: PubMed
    Score: 0.171
  22. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589.
    View in: PubMed
    Score: 0.166
  23. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015 Oct 22; 526(7574):525-30.
    View in: PubMed
    Score: 0.159
  24. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014 Dec 08; 26(6):813-825.
    View in: PubMed
    Score: 0.150
  25. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014 Jul 17; 124(3):453-62.
    View in: PubMed
    Score: 0.145
  26. Somatic mutation as a mechanism of Wnt/ß-catenin pathway activation in CLL. Blood. 2014 Aug 14; 124(7):1089-98.
    View in: PubMed
    Score: 0.144
  27. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65.
    View in: PubMed
    Score: 0.137
  28. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013 Feb 14; 152(4):714-26.
    View in: PubMed
    Score: 0.132
  29. Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology. 2012 Oct 01; 1(7):1095-1103.
    View in: PubMed
    Score: 0.129
  30. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin Cancer Res. 2012 Oct 15; 18(20):5761-72.
    View in: PubMed
    Score: 0.128
  31. Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50.
    View in: PubMed
    Score: 0.123
  32. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29; 365(26):2497-506.
    View in: PubMed
    Score: 0.122
  33. Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest. 2011 Apr; 121(4):1574-84.
    View in: PubMed
    Score: 0.116
  34. Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res. 2010 Feb 15; 70(4):1344-55.
    View in: PubMed
    Score: 0.107
  35. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res. 2010 Feb 01; 70(3):906-15.
    View in: PubMed
    Score: 0.107
  36. Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2008 Sep; 36(9):1205-15.
    View in: PubMed
    Score: 0.096
  37. Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma. 2002 Dec; 43(12):2281-9.
    View in: PubMed
    Score: 0.065
  38. Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. Nat Commun. 2021 09 13; 12(1):5395.
    View in: PubMed
    Score: 0.060
  39. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021 08 10; 5(15):2982-2986.
    View in: PubMed
    Score: 0.060
  40. Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment. Nat Cancer. 2021 Jul; 2(7):758-772.
    View in: PubMed
    Score: 0.059
  41. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021 03; 27(3):515-525.
    View in: PubMed
    Score: 0.057
  42. Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discov. 2021 01; 2(1):54-69.
    View in: PubMed
    Score: 0.057
  43. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 2000 Sep; 106(5):705-14.
    View in: PubMed
    Score: 0.056
  44. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020 06; 26(6):909-918.
    View in: PubMed
    Score: 0.055
  45. Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy. Sci Rep. 2020 01 20; 10(1):723.
    View in: PubMed
    Score: 0.053
  46. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000 Jan 01; 95(1):352-9.
    View in: PubMed
    Score: 0.053
  47. Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. Am J Hematol. 2019 04; 94(4):446-454.
    View in: PubMed
    Score: 0.050
  48. A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. Cancer Cell. 2019 02 11; 35(2):283-296.e5.
    View in: PubMed
    Score: 0.050
  49. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239.
    View in: PubMed
    Score: 0.050
  50. Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia. Nano Lett. 2012 Dec 12; 12(12):6498-504.
    View in: PubMed
    Score: 0.033
  51. CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother. 2013 Feb; 62(2):347-57.
    View in: PubMed
    Score: 0.032
  52. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res. 2012 Jul 15; 18(14):3791-802.
    View in: PubMed
    Score: 0.031
  53. Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood. 2001 Aug 15; 98(4):1116-21.
    View in: PubMed
    Score: 0.015
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.